RECRUITING

NSAIDs vs. Coxibs in the Presence of Aspirin

Conditions

Rheumatoid Arthritis Cardiovascular Diseases

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The objectives of this single site, randomized, crossover study is to evaluate the pharmacodynamic interactions between aspirin, NSAIDs and Coxibs with respect to platelet function, biomarkers of inflammation and endothelial function.

Official Title

NSAIDs vs. Coxibs in the Presence of Aspirin: Effects on Platelet Function, Endothelial Function, and Biomarkers of Inflammation in Subjects With Rheumatoid Arthritis and Increased Cardiovascular Risk or Cardiovascular Disease

Quick Facts

Study Start:2018-09-22

Study Completion:2019-11-24

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT03699293

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Age 18-75 years of age for patients who regularly use NSAIDs. 2. Age 18-65 years of age for patients who do not regularly use NSAIDs 3. Able to give informed consent 4. Subjects with CVD or increased CV risk. Please see definitions for each criteria below: * Increased CV risk (Subjects should have at least 3 of the following) * \> 55 years of age * Hypertension * Dyslipidemia (LDL \> 160 mg/dL or HDL \< 40 mg/dL in females and \< 35 mg/dL in males or subjects currently receiving lipid lowering therapy as standard of care (i.e. statin drugs, prescription ω 3-acid ethyl esters, fibrates or prescription niacin \[≥1,000 mg/d\]) * Family history of premature CV disease (MI, angina pectoris, heart failure, cardiac death or coronary revascularization, stroke, carotid endarterectomy, or other arterial surgery or angioplasty for atherosclerotic vascular disease in a parent, grandparent, or sibling with symptom onset or diagnosis before age 55 y for males and 65 y for females) * Current smoker * Left ventricular hypertrophy * Documented ankle brachial index of \<0.9 * History of microalbuminuria, urine protein-creatinine ratio of \>2 * CV disease (defined as one of the following): * Calcium score of \>0 * ≥ 50 % occlusion of a coronary artery by angiography * ≥ 50 % occlusion of a carotid artery by angiography or ultrasound * History of stable angina * Symptomatic peripheral arterial disease * Prior MI, unstable angina, percutaneous coronary intervention, CABG, TIA, ischemic stroke, carotid endarterectomy, or other arterial surgery or angioplasty, which have occurred \> 3 months prior to screening visit * Diabetes Mellitus type 1 or 2 (considered a CV disease equivalent). * Clinical diagnosis of rheumatoid arthritis, as determined by individual patient and physician, requiring daily treatment with NSAIDs.	1. Unstable angina, MI, CVA, CABG \<3 months from screening visit 2. Planned coronary, cerebrovascular, or peripheral revascularization 3. Undergone major surgery within 3 months prior to screening visit or has planned major surgery during the study period 4. Uncontrolled hypertension (SBP \>190, DBP \>100 mm Hg) during screening visit 5. Uncontrolled arrhythmia \< 3 months from screening visit 6. NYHA class III-IV heart failure or if available, ejection fraction ≤ 35 % 7. Within 6 months prior to screening visit, a history of ACS or hospitalization for heart failure 8. Oral corticosteroid, prednisone (or equivalent) \> 20 mg daily 9. Anticoagulation therapy 10. Antiplatelet therapy except for aspirin 11. GI ulceration \< 60 days before screening visit 12. GI bleeding, perforation, obstruction \< 6 months of screening visit 13. Inflammatory bowel disease, diverticulitis active \< 6 months of screening visit 14. AST, ALT, or BUN \>2x the upper limit normal (within 30 days prior to screening visit) 15. Creatinine level \>1.7 mg/dL in men, 1.5 mg/dL in women (within 30 days prior to screening visit) 16. On fluconazole, methotrexate, or lithium therapy 17. Malignancy \< 5 years before screening visit 18. Other known, active, significant GI, hepatic, renal, or coagulation disorders 19. Allergy, allergic-type reactions or hypersensitivity (e.g. asthma, urticaria, etc.) to any of the study medications and its components (i.e. sulfonamides) 20. History of any disease of condition that, in the opinion of the investigator would place the subject at an unacceptable risk to participate in this study 21. Any clinically relevant abnormal findings in physical examination, vital signs, or previous laboratory works that, in the opinion of the investigator, may compromise the safety of the subject to participate 22. Subjects who are legally institutionalized 23. Lactating females or females of childbearing potential except for those who are surgically sterile or postmenopausal-

Inclusion Criteria

Exclusion Criteria

1. Age 18-75 years of age for patients who regularly use NSAIDs.
2. Age 18-65 years of age for patients who do not regularly use NSAIDs
3. Able to give informed consent
4. Subjects with CVD or increased CV risk. Please see definitions for each criteria below:
* Increased CV risk (Subjects should have at least 3 of the following)
* \> 55 years of age
* Hypertension
* Dyslipidemia (LDL \> 160 mg/dL or HDL \< 40 mg/dL in females and \< 35 mg/dL in males or subjects currently receiving lipid lowering therapy as standard of care (i.e. statin drugs, prescription ω 3-acid ethyl esters, fibrates or prescription niacin \[≥1,000 mg/d\])
* Family history of premature CV disease (MI, angina pectoris, heart failure, cardiac death or coronary revascularization, stroke, carotid endarterectomy, or other arterial surgery or angioplasty for atherosclerotic vascular disease in a parent, grandparent, or sibling with symptom onset or diagnosis before age 55 y for males and 65 y for females)
* Current smoker
* Left ventricular hypertrophy
* Documented ankle brachial index of \<0.9
* History of microalbuminuria, urine protein-creatinine ratio of \>2
* CV disease (defined as one of the following):
* Calcium score of \>0
* ≥ 50 % occlusion of a coronary artery by angiography
* ≥ 50 % occlusion of a carotid artery by angiography or ultrasound
* History of stable angina
* Symptomatic peripheral arterial disease
* Prior MI, unstable angina, percutaneous coronary intervention, CABG, TIA, ischemic stroke, carotid endarterectomy, or other arterial surgery or angioplasty, which have occurred \> 3 months prior to screening visit
* Diabetes Mellitus type 1 or 2 (considered a CV disease equivalent).
* Clinical diagnosis of rheumatoid arthritis, as determined by individual patient and physician, requiring daily treatment with NSAIDs.

1. Unstable angina, MI, CVA, CABG \<3 months from screening visit
2. Planned coronary, cerebrovascular, or peripheral revascularization
3. Undergone major surgery within 3 months prior to screening visit or has planned major surgery during the study period
4. Uncontrolled hypertension (SBP \>190, DBP \>100 mm Hg) during screening visit
5. Uncontrolled arrhythmia \< 3 months from screening visit
6. NYHA class III-IV heart failure or if available, ejection fraction ≤ 35 %
7. Within 6 months prior to screening visit, a history of ACS or hospitalization for heart failure
8. Oral corticosteroid, prednisone (or equivalent) \> 20 mg daily
9. Anticoagulation therapy
10. Antiplatelet therapy except for aspirin
11. GI ulceration \< 60 days before screening visit
12. GI bleeding, perforation, obstruction \< 6 months of screening visit
13. Inflammatory bowel disease, diverticulitis active \< 6 months of screening visit
14. AST, ALT, or BUN \>2x the upper limit normal (within 30 days prior to screening visit)
15. Creatinine level \>1.7 mg/dL in men, 1.5 mg/dL in women (within 30 days prior to screening visit)
16. On fluconazole, methotrexate, or lithium therapy
17. Malignancy \< 5 years before screening visit
18. Other known, active, significant GI, hepatic, renal, or coagulation disorders
19. Allergy, allergic-type reactions or hypersensitivity (e.g. asthma, urticaria, etc.) to any of the study medications and its components (i.e. sulfonamides)
20. History of any disease of condition that, in the opinion of the investigator would place the subject at an unacceptable risk to participate in this study
21. Any clinically relevant abnormal findings in physical examination, vital signs, or previous laboratory works that, in the opinion of the investigator, may compromise the safety of the subject to participate
22. Subjects who are legally institutionalized
23. Lactating females or females of childbearing potential except for those who are surgically sterile or postmenopausal-

Contacts and Locations

Study Contact

Kevin Bliden, BS, MBA

CONTACT

(703) 776-7702

kevin.bliden@inova.org

Emiliya Bakalska, BA

CONTACT

(410) 367-2592

emiliya.bakalska@inova.org

Principal Investigator

Kevin Bliden, BS, MBA

STUDY_DIRECTOR

Inova Health Care Services

Study Locations (Sites)

Inova Heart and Vascular Institute

Falls Church, Virginia, 22042

United States

Collaborators and Investigators

Sponsor: Inova Health Care Services

Kevin Bliden, BS, MBA, STUDY_DIRECTOR, Inova Health Care Services

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-09-22

Study Completion Date2019-11-24

Study Record Updates

Study Start Date2018-09-22

Study Completion Date2019-11-24

Terms related to this study

Additional Relevant MeSH Terms

Rheumatoid Arthritis
Cardiovascular Diseases